Summary of Annual General Meeting of Shareholders
- Jan Nooitgedagt appointed as member of the Executive Board; succeeds Jos Streppel as CFO
- Alex Wynaendts reviews Aegon’s position in financial turmoil
- Dudley Eustace reappointed to the Supervisory Board, extending his chairmanship to 2010
- Dividend 2008
- Resolutions of the AGM
Jan J. Nooitgedagt has officially been appointed as a member of the Executive Board of Aegon N.V. following the Group’s Annual General Meeting of Shareholders (AGM), held today in The Hague. Mr. Nooitgedagt succeeds Joseph B.M. Streppel as chief financial officer effective immediately. Mr. Streppel announced last January his intention to retire after more than 35 years with Aegon, and as CFO for the past ten years.
“I am pleased and honored to be joining Aegon as chief financial officer and a member of the Executive Board. While these are indeed challenging times for the global insurance industry and financial sector in general, I look forward to working closely with Alex Wynaendts to position Aegon for the opportunities that lie ahead, building on the solid foundation which has been established in recent years”, said Jan Nooitgedagt.
Alex Wynaendts comments on financial turmoil
“During 2008, we took decisive steps to strengthen Aegon’s position in the financial crisis which continues to threaten market and consumer confidence. We are confident that our actions to enhance Aegon’s capital position, reduce costs, and put into place sufficient contingencies to withstand further market distress are the right ones to deal with the adverse effects we have experienced. There can be no question about Aegon’s ability to fulfill its long-term obligations to its customers. Moreover, we are committed to returning to an era of growth and value creation for our shareholders as market conditions normalize.”
Dudley Eustace reappointed to the Supervisory Board until 2010
As announced earlier, given the recent changes in the composition of the Supervisory Board, it was deemed prudent to request Dudley Eustace to remain on as Chairman for an additional year, beyond his term which expires this year in order to ensure continuity. Mr. Eustace has agreed to this request. As such, a resolution has been put to shareholders for their approval at today’s AGM to reappoint Mr. Eustace to the Supervisory Board for one year.
Rob Routs will succeed Mr. Eustace as Chairman of the Supervisory Board at the AGM in April 2010.
As part of broader measures to preserve capital in light of the global financial crisis, Aegon decided to make no final dividend payment on its common shares. In September 2008, Aegon paid an interim dividend of EUR 0.30 a share.
Resolutions of the AGM
The decisions taken by the shareholders at the AGM include the following:
Supervisory Board changes in composition
Mr. S. Levy was reappointed as a member of the Supervisory Board for a term of four years as of April 22, 2009.
Mr. A.W.H. Docters van Leeuwen was appointed as a member of the Supervisory Board for a term of four years as of April 22, 2009.
Mr. W.F.C. Stevens has stepped down as member of the Supervisory Board.
Executive Board changes in composition
At the end of the AGM, Mr. J.B.M. Streppel stepped down as member of the Executive Board and CFO.
Mr. J.J. Nooitgedagt succeeded Mr. Streppel as member of the Executive Board and CFO for a term of four years as of April 22, 2009.
The AGM adopted the annual accounts for the financial year 2008 and the members of the Executive Board and Supervisory Board were released from liability for their duties.
Authorization Executive Board
The AGM has authorized the Executive Board to issue common shares, to restrict/exclude pre-emptive rights upon issuing common shares and to acquire shares in the company.
As an international life insurance, pension and investment company based in The Hague, Aegon has businesses in over twenty markets in the Americas, Europe and Asia. Aegon companies employ approximately 31,500 people and have over 40 million customers across the globe.
|Underlying earnings before tax||EUR 1.57 billion||EUR 2.64 billion|
|New life sale||EUR 2.63 billion||EUR 3.27 billion|
|Gross deposits||EUR 40.75 billion||EUR 44.53 billion|
|Revenue generating investments
(At December 31)
|EUR 332 billion||EUR 370 billion|